How Much Does Rezdiffra (Resmetirom) Cost in District of Columbia in 2026?

Rezdiffra Retail Price in the District of Columbia

The standard retail price for Rezdiffra in D.C. is $3,500 per month, matching Madrigal Pharmaceuticals' national wholesale acquisition cost. That figure applies to both the 80 mg and 100 mg tablet strengths, dosed once daily. This positions resmetirom at $42,000 per year before any insurance adjustments or discount programs.

Retail pricing across D.C. pharmacies shows little variation because Rezdiffra is distributed through a limited specialty pharmacy network rather than open retail channels. CVS Specialty, Optum Specialty, and Accredo currently handle most Rezdiffra dispensing in the district. Patients who attempt to fill a prescription at a standard retail pharmacy will typically be redirected to one of these specialty outlets. The FDA-approved prescribing information for Rezdiffra specifies weight-based dosing: 80 mg daily for patients weighing <100 kg and 100 mg daily for those at or above that threshold [1]. Both dose strengths are priced identically, so body weight does not affect the monthly cost.

Compared to the injectable biologics and anti-obesity medications often used in overlapping metabolic populations, Rezdiffra sits in a moderate-to-high specialty tier. Semaglutide 2.4 mg (Wegovy) runs approximately $1,349 per month at list price, while obeticholic acid (Ocaliva), which lost its NASH indication in 2024, had carried a list price above $6,000 monthly before withdrawal from the MASH market.

D.C. Medicaid Coverage for Rezdiffra

District of Columbia Medicaid covers Rezdiffra with prior authorization. The D.C. Department of Health Care Finance (DHCF) added resmetirom to its preferred drug list in late 2024 following the FDA's accelerated approval in March 2024 for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced hepatic fibrosis (stages F2 and F3) [1].

Prior authorization requirements in D.C. Medicaid typically demand documented evidence of MASH via liver biopsy or validated non-invasive testing (FibroScan with a liver stiffness measurement of 8.0 kPa or higher, or an FIB-4 score above 1.3), plus confirmation of fibrosis stage F2 or F3. Patients with compensated or decompensated cirrhosis (F4) fall outside the approved indication and will not receive Medicaid authorization for Rezdiffra. The prescriber must also be a hepatologist, gastroenterologist, or endocrinologist, or the request must include a specialist consultation note.

D.C. Medicaid enrollees pay no monthly premium and face minimal copays for specialty medications, so out-of-pocket cost after approval is typically $0 to $3 per fill. The approval period runs 12 months, with renewal contingent on documented adherence and follow-up liver assessment. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg produced MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks versus 9.7% on placebo, a result that supported the clinical rationale behind formulary inclusion [2].

Commercial Insurance Coverage in D.C.

Most major commercial insurers operating in the District of Columbia have added Rezdiffra to their specialty formularies, though coverage almost universally requires prior authorization and, in many cases, step therapy.

CareFirst BlueCross BlueShield, the dominant commercial plan in the D.C. metro area, classifies Rezdiffra as a specialty tier 5 drug with prior authorization. The plan requires documented fibrosis staging (F2 or F3), a confirmed MASH diagnosis, and evidence that lifestyle modifications (diet, exercise, weight management) were attempted for at least 6 months prior to the prescription. Aetna and UnitedHealthcare plans sold through the D.C. Health Benefit Exchange (DC Health Link) follow similar criteria, with UnitedHealthcare also requiring documentation of a BMI at or above 25 kg/m² or the presence of type 2 diabetes.

Kaiser Permanente of the Mid-Atlantic, which serves a significant share of D.C. federal employees, has restricted Rezdiffra to its specialty formulary with mandatory hepatologist referral. Federal Employees Health Benefits (FEHB) plans, which cover a large percentage of the district's working population, generally follow the same prior authorization structure as their commercial counterparts.

After prior authorization approval, commercially insured patients in D.C. typically face specialty copays ranging from $100 to $500 per month depending on plan design. This is where the manufacturer savings program becomes significant.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay assistance program that can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients in the District of Columbia. The card covers up to $13 to 000 in annual copay assistance per calendar year.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Rezdiffra (even with prior authorization pending), must not be enrolled in any federal or state government-funded healthcare program (Medicare, Medicaid, TRICARE, VA), and must be a U.S. resident. The savings card is activated through the Rezdiffra support hub, RezdiffraCares, which also provides nurse case managers and prior authorization assistance.

For D.C. patients with commercial insurance, the savings card effectively eliminates monthly out-of-pocket cost in most scenarios. A patient with a $350 monthly specialty copay would use $4,200 of the $13,000 annual cap, leaving substantial headroom. Patients whose plans impose coinsurance (for example, 20% of a $3,500 drug) face a $700 monthly coinsurance obligation, which would exhaust the $13,000 cap by month 18. In those cases, patients should coordinate with their plan's out-of-pocket maximum, which resets annually under ACA rules.

Patients enrolled in D.C. Medicaid, Medicare Part D, or TRICARE are not eligible for the savings card. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-funded beneficiaries.

Compounded Resmetirom in D.C.

Compounded resmetirom is available through licensed 503A compounding pharmacies in the District of Columbia. This route exists as a legal option under federal law (the Drug Quality and Security Act, Section 503A), which permits patient-specific compounding when a licensed prescriber writes an individualized prescription.

503A compounding pharmacies in D.C. operate under oversight from the D.C. Board of Pharmacy and must comply with United States Pharmacopeia (USP) chapters 795 and 797. Because resmetirom is not on the FDA's "Demonstrably Difficult to Compound" list as of May 2026, 503A pharmacies can legally compound it from bulk pharmaceutical-grade resmetirom powder.

Cost for compounded resmetirom varies but is typically priced well below the $3,500 brand-name cost. Some D.C.-area compounding pharmacies offer resmetirom formulations for a fraction of that figure, though pricing is not standardized and depends on the pharmacy's sourcing and overhead. Patients considering this route should verify that the compounding pharmacy holds current D.C. Board of Pharmacy licensure and adheres to USP compounding standards.

An important clinical consideration: compounded resmetirom has not undergone the same bioequivalence testing as FDA-approved Rezdiffra tablets. The MAESTRO-NASH trial used the proprietary Madrigal formulation exclusively [2]. Prescribers and patients should weigh the cost savings against the absence of formal bioequivalence data for compounded versions.

Telehealth Prescribing in D.C.

Rezdiffra can be prescribed via telehealth in the District of Columbia. D.C. telehealth regulations, updated in 2023 under the D.C. Telehealth Reimbursement Act, permit prescribing of non-controlled substances through audio-video consultations without requiring an in-person visit. Resmetirom is not a controlled substance, so it falls within the scope of telehealth prescribing without restriction.

This opens a practical access pathway for D.C. residents. A hepatologist or gastroenterologist licensed in D.C. can evaluate imaging results, review lab work (ALT, AST, FIB-4, FibroScan reports), and prescribe Rezdiffra in a single telehealth encounter. Several national telehealth liver-disease platforms now offer MASH-focused consultations that include Rezdiffra evaluation.

For prior authorization purposes, insurers in D.C. do not distinguish between telehealth and in-person encounters. A telehealth-initiated prescription carries the same prior authorization pathway as one written after a clinic visit. The Endocrine Society's 2023 clinical practice guidelines on NAFLD/MASH management support the use of non-invasive fibrosis assessment tools in clinical decision-making, which aligns well with telehealth-based evaluation [3].

How Rezdiffra Works and Who Qualifies

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist. It activates THR-β in the liver without stimulating THR-α in the heart or bone, which separates it mechanistically from systemic thyroid hormones. By activating hepatic THR-β, resmetirom increases mitochondrial fatty acid oxidation, reduces hepatic lipogenesis, and lowers circulating LDL cholesterol and triglycerides. The net effect is reduced liver fat, decreased hepatocyte ballooning, and improvement in fibrosis markers [2].

The FDA approved Rezdiffra under the accelerated approval pathway in March 2024, based on the surrogate endpoint of MASH resolution without worsening fibrosis at 52 weeks. In the MAESTRO-NASH key trial (N=966), the 100 mg dose achieved MASH resolution in 29.9% of patients versus 9.7% on placebo (P<0.001), and fibrosis improvement by at least one stage in 25.9% versus 14.2% on placebo [2]. A confirmatory outcomes trial (MAESTRO-OUTCOMES) is ongoing and expected to report by 2028.

Dr. Rohit Loomba, director of the MASLD Research Center at UC San Diego, noted at the 2024 AASLD Liver Meeting: "Resmetirom represents the first approved pharmacotherapy for MASH, filling a gap that has persisted for decades in hepatology."

The American Association for the Study of Liver Diseases (AASLD practice guidance, 2023) recommends considering pharmacotherapy for MASH patients with significant fibrosis (F2 or higher) who have not achieved adequate improvement through lifestyle intervention alone [4]. Rezdiffra's labeled indication aligns directly with this guidance.

Qualifying patients must have biopsy-confirmed or non-invasively assessed MASH with fibrosis stage F2 or F3. Patients with cirrhosis (F4), decompensated liver disease, or active hepatocellular carcinoma are excluded from the indication. The drug is contraindicated in pregnancy.

Side Effects and Monitoring Costs

The most common adverse effects of resmetirom in clinical trials were diarrhea (26.7% vs. 15.8% placebo at 100 mg), nausea (22.2% vs. 12.8%), and abdominal pain (5.4% vs. 3.3%) [2]. These gastrointestinal effects were typically mild to moderate and tended to decrease after the first 4 to 8 weeks of treatment.

Lab monitoring adds a modest cost layer on top of the drug price. The FDA prescribing information recommends checking thyroid function tests (TSH, free T4) at baseline and periodically during treatment, along with liver function tests (ALT, AST) [1]. A standard hepatic function panel costs $15 to $50 at D.C. commercial labs, and a thyroid panel runs $30 to $80 without insurance. For insured patients, these labs are typically covered as part of routine disease monitoring with minimal or no copay.

Dr. Arun Sanyal, a hepatologist at Virginia Commonwealth University who served as a MAESTRO-NASH investigator, stated in a 2024 interview with the American Gastroenterological Association: "The safety profile of resmetirom is favorable compared to what we have seen with other hepatic-targeted agents, and the GI side effects are manageable for the majority of patients."

Lipid changes are a secondary benefit worth noting. In MAESTRO-NASH, the 100 mg dose reduced LDL cholesterol by approximately 16% and triglycerides by approximately 20% from baseline at 52 weeks [2]. For D.C. patients already on statins for cardiovascular risk reduction, this additive lipid effect could reduce the need for intensified statin dosing.

Comparing All D.C. Cost Pathways

A D.C. resident filling Rezdiffra can expect one of several cost scenarios depending on coverage status:

Commercial insurance with savings card: $0 per month (up to $13,000 annual cap). This is the lowest-cost pathway for most working-age D.C. residents with employer-sponsored or ACA marketplace coverage.

Commercial insurance without savings card: $100 to $700 per month depending on plan tier and coinsurance structure. Specialty tier copays in D.C. commercial plans average $250 to $400 for a 30-day supply.

D.C. Medicaid: $0 to $3 per month after prior authorization approval.

Medicare Part D: Variable, but patients in the coverage gap (donut hole) faced significant exposure prior to the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect January 2025. Medicare Part D enrollees now pay no more than $2,000 per year across all covered drugs, which limits Rezdiffra exposure substantially.

Cash pay (no insurance): $3,500 per month.

Compounded resmetirom (503A): Pricing varies by pharmacy; substantially below brand-name cost but without bioequivalence data.

For a patient on Medicare Part D with no other covered specialty drugs, Rezdiffra would hit the $2,000 annual cap within the first month at list price, meaning the remaining 11 months of the year would carry $0 additional out-of-pocket cost for Rezdiffra specifically.